Catalyst Pharmaceuticals, Inc.
CPRX
$21.12
-$0.21-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.56% | 28.26% | 25.33% | 23.23% | 15.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.56% | 28.26% | 25.33% | 23.23% | 15.40% |
| Cost of Revenue | 44.35% | 43.08% | -76.94% | 14.94% | 11.79% |
| Gross Profit | 43.42% | 25.43% | 2,084.28% | 24.81% | 16.07% |
| SG&A Expenses | -0.06% | 5.13% | 36.71% | 43.44% | 57.94% |
| Depreciation & Amortization | 0.01% | 3.15% | 10.11% | 10.08% | 43.07% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.35% | 14.67% | -44.39% | 29.46% | 43.46% |
| Operating Income | 133.60% | 50.73% | 236.90% | 16.16% | -23.82% |
| Income Before Tax | 145.06% | 58.82% | 250.46% | 15.00% | -22.04% |
| Income Tax Expenses | 150.24% | 53.80% | 283.56% | 39.48% | -24.93% |
| Earnings from Continuing Operations | 143.77% | 60.53% | 242.65% | 8.03% | -21.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.77% | 60.53% | 242.65% | 8.03% | -21.28% |
| EBIT | 133.60% | 50.73% | 236.90% | 16.16% | -23.82% |
| EBITDA | 99.22% | 42.23% | 310.90% | 15.22% | -13.39% |
| EPS Basic | 134.37% | 42.91% | 227.81% | -2.87% | -28.85% |
| Normalized Basic EPS | 118.29% | 39.29% | 232.64% | 7.61% | -26.75% |
| EPS Diluted | 136.84% | 41.39% | 220.69% | 0.00% | -26.92% |
| Normalized Diluted EPS | 120.71% | 40.95% | 225.76% | 9.15% | -25.17% |
| Average Basic Shares Outstanding | 3.99% | 12.35% | 11.60% | 11.22% | 10.65% |
| Average Diluted Shares Outstanding | 2.88% | 11.01% | 17.68% | 9.66% | 8.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |